Molecular Medicine

, Volume 14, Issue 11–12, pp 741–751 | Cite as

Adipokines and Insulin Resistance

  • Katja Rabe
  • Michael Lehrke
  • Klaus G. Parhofer
  • Uli C. Broedl
Review Article


Obesity is associated with an array of health problems in adult and pediatric populations. Understanding the pathogenesis of obesity and its metabolic sequelae has advanced rapidly over the past decades. Adipose tissue represents an active endocrine organ that, in addition to regulating fat mass and nutrient homeostasis, releases a large number of bioactive mediators (adipokines) that signal to organs of metabolic importance including brain, liver, skeletal muscle, and the immune system— thereby modulating hemostasis, blood pressure, lipid and glucose metabolism, inflammation, and atherosclerosis. In the present review, we summarize current data on the effect of the adipose tissue-derived hormones adiponectin, chemerin, leptin, omentin, resistin, retinol binding protein 4, tumor necrosis factor-α and interleukin-6, vaspin, and visfatin on insulin resistance.



This work was supported by a grant from the Deutsche Forschungsgemeinschaft (BR 2151/4-1 to UCB).


  1. 1.
    Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol. Chem. 270:26746–9.CrossRefGoogle Scholar
  2. 2.
    Hu E, Liang P, Spiegelman BM. (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. JBiol. Chem. 271:10697–703.CrossRefGoogle Scholar
  3. 3.
    Hotta K, et al. (2001) Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 50:1126–33.CrossRefGoogle Scholar
  4. 4.
    Fruebis J, et al. (2001) Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98:2005–10.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. (2001) The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7:947–53.CrossRefGoogle Scholar
  6. 6.
    Yamauchi T, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7:941–6.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Yamauchi T, et al. (2003) Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J. Biol. Chem. 278:2461–8.CrossRefGoogle Scholar
  8. 8.
    Combs TP, et al. (2004) A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology 145:367–83.CrossRefGoogle Scholar
  9. 9.
    Kubota N, et al. (2002) Disruption of adiponectin causes insulin resistance and neointimal formation. JBiol. Chem. 277:25863–6.CrossRefGoogle Scholar
  10. 10.
    Maeda N, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8:731–7.CrossRefGoogle Scholar
  11. 11.
    Nawrocki AR, et al. (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol. Chem. 281:2654–60.CrossRefGoogle Scholar
  12. 12.
    Okamoto M, et al. (2008) Adiponectin induces insulin secretion in vitro and in vivo at a low glucose concentration. Diabetologia 51:827–35.CrossRefGoogle Scholar
  13. 13.
    Kubota N, et al. (2007) Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 6:55–68.CrossRefGoogle Scholar
  14. 14.
    Cnop M, et al. (2003) Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–69.CrossRefGoogle Scholar
  15. 15.
    Tschritter O, et al. (2003) Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–43.CrossRefGoogle Scholar
  16. 16.
    Weyer C, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab. 86:1930–5.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Hanley AJ, et al. (2007) Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans. J. Clin. Endocrinol. Metab. 92:2665–71.CrossRefGoogle Scholar
  18. 18.
    Bacha F, Saad R, Gungor N, Arslanian SA. (2004) Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 27:547–52.CrossRefGoogle Scholar
  19. 19.
    Hivert MF, et al. (2008) Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J. Clin. Endocrinol. Metab. 93:3165–72.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Hotta K, et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20:1595–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gilardini L, et al. (2006) Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 189:401–7.CrossRefGoogle Scholar
  22. 22.
    Mohan V, et al. (2005) Association of low adiponectin levels with the metabolic syndrome— the Chennai Urban Rural Epidemiology Study (CURES-4). Metabolism 54:476–81.CrossRefGoogle Scholar
  23. 23.
    Wang J, et al. (2008) Adiponectin and metabolic syndrome in middle-aged and elderly Chinese. Obesity (Silver Spring) 16:172–8.CrossRefGoogle Scholar
  24. 24.
    Pellmé F, et al. (2003) Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients. Diabetes 52:1182–6.CrossRefGoogle Scholar
  25. 25.
    Winzer C, et al. (2004) Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus. Diabetes Care 27:1721–7.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Lindsay RS, et al. (2002) Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360:57–8.CrossRefGoogle Scholar
  27. 27.
    Daimon M, et al. (2003) Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 26:2015–20.CrossRefGoogle Scholar
  28. 28.
    Snehalatha C, et al. (2003) Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians. Diabetes Care 26:3226–9.CrossRefGoogle Scholar
  29. 29.
    Spranger J, et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361:226–8.CrossRefGoogle Scholar
  30. 30.
    Duncan BB, et al. (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53:2473–8.CrossRefGoogle Scholar
  31. 31.
    Krakoff J, et al. (2003) Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care 26:1745–51.CrossRefGoogle Scholar
  32. 32.
    Snijder MB, et al. (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: The Hoorn Study. Diabetes Care 29:2498–503.CrossRefGoogle Scholar
  33. 33.
    Mather KJ, et al. (2008) Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes 57:980–6.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Menzaghi C, Trischitta V, Doria A. (2007) Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 56:1198–209.CrossRefGoogle Scholar
  35. 35.
    Waki H, et al. (2003) Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. JBiol. Chem. 278:40352–63.CrossRefGoogle Scholar
  36. 36.
    Wang Y, et al. (2006) Posttranslational modifications on the four conserved lysine residues within the collagenous domain of adiponectin are required for the formation of its high-molecular-weight oligomeric complex. J Biol. Chem. 281:16391–400.CrossRefGoogle Scholar
  37. 37.
    Pajvani UB, et al. (2004) Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol. Chem. 279:12152–62.CrossRefGoogle Scholar
  38. 38.
    Blüher M, et al. (2007) Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care 30:280–5.CrossRefGoogle Scholar
  39. 39.
    Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. (2006) Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 55:249–59.CrossRefGoogle Scholar
  40. 40.
    Hara K, Horikoshi M, Yamauchi T, et al. (2006) Measurement of the high molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357–62.CrossRefGoogle Scholar
  41. 41.
    von Eynatten M, Lepper PM, Humpert PM. (2007) Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays: response to Bluher et al. Diabetes Care 30:e67.CrossRefGoogle Scholar
  42. 42.
    Combs TP, et al. (2002) Induction of adipocyte complement-related protein of 30 kilodaltons by PPARgamma agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998–1007.CrossRefGoogle Scholar
  43. 43.
    Yu JG, et al. (2002) The effect of thiazolidine-diones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51:2968–74.CrossRefGoogle Scholar
  44. 44.
    Maeda N, et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094–9.CrossRefGoogle Scholar
  45. 45.
    Yamauchi T, et al. (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–9.CrossRefGoogle Scholar
  46. 46.
    Tsuchida A, et al. (2004) Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol. Chem. 279:30817–22.CrossRefGoogle Scholar
  47. 47.
    Yamauchi T, et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat. Med. 13:332–9.CrossRefGoogle Scholar
  48. 48.
    Hug C, et al. (2004) T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc. Natl. Acad. Sci. U. S. A. 101:10308–13.PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Bjursell M, et al. (2007) Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes 56:583–93.CrossRefGoogle Scholar
  50. 50.
    Liu Y, et al. (2007) Deficiency of adiponectin receptor 2 reduces diet-induced insulin resistance but promotes type 2 diabetes. Endocrinology 148:683–92.CrossRefGoogle Scholar
  51. 51.
    Blüher M, et al. (2007) Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 30:3110–5.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Rasmussen MS, et al. (2006) Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and fat depots. Obesity (Silver Spring) 14:28–35.CrossRefGoogle Scholar
  53. 53.
    Li W, et al. 2007) Insulin-sensitizing effects of thiazolidinediones are not linked to adiponectin receptor expression in human fat or muscle. Am. J. Physiol. Endocrinol. Metab. 292:E1301–7.CrossRefGoogle Scholar
  54. 54.
    Nannipieri M, et al. (2007) Pattern of expression of adiponectin receptors in human adipose tissue depots and its relation to the metabolic state. Int. J. Obes. (Lond.) 31:1843–8.CrossRefGoogle Scholar
  55. 55.
    Zhang J, Holt H, Wang C, Hadid OH, Byrne CD. (2005) Expression of AdipoR1 in vivo in skeletal muscle is independently associated with measures of truncal obesity in middle-aged Caucasian men. Diabetes Care 28:2058–60.CrossRefGoogle Scholar
  56. 56.
    Blüher M, et al. (2006) Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J. Clin. Endocrinol. Metab. 91:2310–6.CrossRefGoogle Scholar
  57. 57.
    Debard C, et al. (2004) Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of Type 2 diabetic patients. Diabetologia 47:917–25.CrossRefGoogle Scholar
  58. 58.
    Civitarese AE, et al. (2004) Adiponectin receptors gene expression and insulin sensitivity in nondiabetic Mexican Americans with or without a family history of Type 2 diabetes. Diabetologia 47:816–20.CrossRefGoogle Scholar
  59. 59.
    Staiger H, et al. (2004) Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo parameters of glucose and lipid metabolism. Diabetes 53:2195–201.CrossRefGoogle Scholar
  60. 60.
    Crimmins NA, Martin LJ. (2007) Polymorphisms in adiponectin receptor genes ADIPOR1 and ADIPOR2 and insulin resistance. Obes. Rev. 8:419–23.CrossRefGoogle Scholar
  61. 61.
    Wittamer V, et al. (2003) Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198:977–985.PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Bozaoglu K, et al. (2007) Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 148:4687–94.CrossRefGoogle Scholar
  63. 63.
    Goralski KB, et al. (2007) Chemerin: A novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol. Chem. 282:28175–88.CrossRefGoogle Scholar
  64. 64.
    Cash JL, et al. (2008) Synthetic chemerin-derived peptides suppress inflammation through ChemR23. J. Exp. Med. 205:767–75.PubMedCentralCrossRefPubMedGoogle Scholar
  65. 65.
    Roh S-G, et al. (2007) Chemerin—A new adipokine that modulates adipogenesis via its own receptor. Biochem. Biophys. Res. Commun. 362:1013–8.CrossRefGoogle Scholar
  66. 66.
    Takahashia M, et al. (2008) Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Letters 582:573–8.CrossRefGoogle Scholar
  67. 67.
    Friedman JM, Halaas JL. (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770.CrossRefGoogle Scholar
  68. 68.
    Elmquist JK, Elias CF, Saper CB. (1999) From lesions to leptin: hypothalamic control of food intake and body weight. Neuron 22:221–232.CrossRefGoogle Scholar
  69. 69.
    Bates SH, Myers MG Jr. (2003) The role of leptin receptor signaling in feeding and neuroendocrine function. Trends Endocrinol. Metab. 14:447–452.CrossRefGoogle Scholar
  70. 70.
    Prodi E, Obici S. (2006) Minireview: the brain as a molecular target for diabetic therapy. Endocrinology 147:2664–9.CrossRefGoogle Scholar
  71. 71.
    Coppari R, et al. (2005) The hypothalamic arcuate nucleus: a key site for mediating leptin’s effects on glucose homeostasis and locomotor activity. Cell Metab. 1:63–72.CrossRefGoogle Scholar
  72. 72.
    Morton GJ, et al. (2005) Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH kinase signaling in mediobasal hypothalamic neurons. Cell Metab. 2:411–420.CrossRefGoogle Scholar
  73. 73.
    Bates SH, Kulkarni RN, Seifert M, Myers MG Jr. (2005) Roles for leptin receptor/STAT3-dependent and -independent signals in the regulation of glucose homeostasis. Cell Metab. 1:169–178.CrossRefGoogle Scholar
  74. 74.
    Kahn BB, Alquier T, Carling D, Hardie DG. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1:15–25.CrossRefGoogle Scholar
  75. 75.
    Minokoshi Y, et al. (2002) Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415:339–43.CrossRefGoogle Scholar
  76. 76.
    Niswender KD, Magnuson MA. (2007) Obesity and the beta cell: lessons from leptin. J. Clin. Invest. 117:2753–6.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Morioka T, et al. (2007) Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J. Clin. Invest. 117:2860–8.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Boghossian S, Dube MG, Torto R, Kalra PS, Kalra SP. (2006) Hypothalamic clamp on insulin release by leptin transgene expression. Peptides 27:3245–54.CrossRefGoogle Scholar
  79. 79.
    Boghossian S, Lecklin AH, Torto R, Kalra PS, Kalra SP. (2005) Suppression of fat deposition for the life time of rodents with gene therapy. Peptides 26:1512–9.CrossRefGoogle Scholar
  80. 80.
    Kieffer TJ, Habener JF. (2000) The adipoinsular axis: effects of leptin on pancreatic beta-cells. Am. J. Physiol. Endocrinol. Metab. 278:E1–E14.CrossRefGoogle Scholar
  81. 81.
    Munzberg H, Myers MG Jr. (2005) Molecular and anatomical determinants of central leptin resistance. Nat. Neurosci. 8:566–570.CrossRefGoogle Scholar
  82. 82.
    Farooqi IS, et al. (2002) Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J. Clin. Invest. 110:1093–103.PubMedCentralCrossRefPubMedGoogle Scholar
  83. 83.
    Oral EA, et al. (2002) Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346:570–8.CrossRefGoogle Scholar
  84. 84.
    Hukshorn CJ, et al. (2000) Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J. Clin. Endocrinol. Metab. 85:4003–9.CrossRefGoogle Scholar
  85. 85.
    El-Haschimi K, Pierroz DD, Hileman SM, Bjørbaek C, Flier JS. (2000) Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity. J. Clin. Invest. 105:1827–32.PubMedCentralCrossRefPubMedGoogle Scholar
  86. 86.
    Unger RH. (2002) Lipotoxic diseases. Annu. Rev. Med. 53:319–36.CrossRefGoogle Scholar
  87. 87.
    Kalra SP. (2008) Central leptin insufficiency syndrome: an interactive etiology for obesity, metabolic and neural diseases and for designing new therapeutic interventions. Peptides 29:127–38.CrossRefGoogle Scholar
  88. 88.
    Yang RZ, et al. (2006) Identification of omentinas a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am. J. Physiol. Endocrinol. Metab. 290:E1253–61.CrossRefGoogle Scholar
  89. 89.
    de Souza Batista CM, et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56:1655–61.CrossRefGoogle Scholar
  90. 90.
    Tan BK, et al. (2008) Omentin-1, a novel adipokine, is decreased in overweight insulinresistant women with polycystic ovary syndrome. Ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 57:801–8.CrossRefGoogle Scholar
  91. 91.
    Steppan CM, et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307–12.CrossRefGoogle Scholar
  92. 92.
    Rajala MW, et al. (2004) Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 53:1671–9.CrossRefGoogle Scholar
  93. 93.
    Rajala MW, Obici S, Scherer PE, Rossetti L. (2003) Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J. Clin. Invest. 111:225–30.PubMedCentralCrossRefPubMedGoogle Scholar
  94. 94.
    Satoh H, et al. (2004) Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J. Clin. Invest. 114:224–31.PubMedCentralCrossRefPubMedGoogle Scholar
  95. 95.
    Pravenec M, et al. (2003) Transgenic and recombinant resistin impair skeletal muscle glucose metabolism in the spontaneously hypertensive rat. J. Biol. Chem. 278:45209–15.CrossRefGoogle Scholar
  96. 96.
    Rangwala SM, et al. (2004) Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes 53:1937–41.CrossRefGoogle Scholar
  97. 97.
    Banerjee RR, et al. (2004) Regulation of fasted blood glucose by resistin. Science 303:1195–8.CrossRefGoogle Scholar
  98. 98.
    Muse ED, et al. (2004) Role of resistin in diet-induced hepatic insulin resistance. J. Clin. Invest. 114:232–9.PubMedCentralCrossRefPubMedGoogle Scholar
  99. 99.
    Kim KH, Zhao L, Moon Y, Kang C, Sul HS. (2004) Dominant inhibitory adipocyte-specific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 101:6780–5.PubMedCentralCrossRefPubMedGoogle Scholar
  100. 100.
    Savage DB, et al. (2001) Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50:2199–2202.CrossRefGoogle Scholar
  101. 101.
    Degawa-Yamauchi M, et al. (2003) Serum resistin (FIZZ3) protein is increased in obese humans. J. Clin. Endocrinol. Metab. 88:5452–5.CrossRefGoogle Scholar
  102. 102.
    Heilbronn LK, et al. (2004) Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J. Clin. Endocrinol. Metab. 89:1844–8.CrossRefGoogle Scholar
  103. 103.
    Youn BS, et al. (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 89:150–6.CrossRefGoogle Scholar
  104. 104.
    Osawa H, et al. (2004) The G/G genotype of a resistin singlenucleotide polymorphism at −420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am. J. Hum. Genet. 75:678–86.PubMedCentralCrossRefPubMedGoogle Scholar
  105. 105.
    Osawa H, et al. (2007) Plasma resistin, associated with single nucleotide plymorphism −402, is correlated with insulin resistance, lower HDL cholesterol, and high sensitivity C-reactive protein in the Japanese general population. Diabetes Care 30:1501–6.CrossRefGoogle Scholar
  106. 106.
    Ochi M, et al. (2007) Frequency of the G/G genotype of resistin single nucleotide polymorphism at −420 appears to be increased in younger-onset type 2 diabetes. Diabetes 56:2834–8.CrossRefGoogle Scholar
  107. 107.
    Gerber M, et al. (2005) Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J. Clin. Endocrinol. Metab. 90:4503–9.CrossRefGoogle Scholar
  108. 108.
    Chen CC, et al. (2005) Serum resistin level among healthy subjects: Relationship to anthro-pometric and metabolic parameters. Metabolism 54:471–5.CrossRefGoogle Scholar
  109. 109.
    Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T. (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin. Lab. 49:571–6.PubMedGoogle Scholar
  110. 110.
    Lee JH, et al. (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J. Clin. Endocrinol. Metab. 88:4848–56.CrossRefGoogle Scholar
  111. 111.
    Kielstein JT, et al. (2003) Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am. J. Kidney Dis. 42:62–6.CrossRefGoogle Scholar
  112. 112.
    Pagano C, et al. (2006) Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J. Clin. Endocrinol. Metab. 91:1081–6.CrossRefGoogle Scholar
  113. 113.
    Perseghin G, et al. (2006) Increased serum resistin in elite endurance athletes with high insulin sensitivity. Diabetologia 49:1893–900.CrossRefGoogle Scholar
  114. 114.
    Beckers S, et al. (2008) Analysis of genetic variations in the resistin gene shows no associations with obesity in women. Obesity 16:905–7.CrossRefGoogle Scholar
  115. 115.
    Kaser S, et al. (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem. Biophys. Res. Commun. 309:286–90.CrossRefGoogle Scholar
  116. 116.
    Nagaev I, Bokarewa M, Tarkowski A, Smith U. (2006) Human resistin is a systemic immune-derived proinflammatory cytokine targeting both leukocytes and adipocytes. PLoS ONE 1:e31.PubMedCentralCrossRefPubMedGoogle Scholar
  117. 117.
    Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. (2005) Resistin, an adipokine with potent proinflammatory properties. J. Immunol. 174:5789–95.CrossRefGoogle Scholar
  118. 118.
    Silswal N, et al. (2005) Human resistin stimulates the pro-inflammatory cytokines TNF-α and IL-12 in macrophages by NF-κB-dependent pathway. Biochem. Biophys. Res. Commun. 334:1092–101.CrossRefGoogle Scholar
  119. 119.
    Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450–7.CrossRefGoogle Scholar
  120. 120.
    Reilly MP, etal. (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–9.CrossRefGoogle Scholar
  121. 121.
    Konrad A, et al. (2007) Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J. Gastroenterol. Hepatol. 19:1070–4.CrossRefGoogle Scholar
  122. 122.
    Sunden-Cullberg J, et al. (2007) Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit. Care Med. 35:1536–42.CrossRefGoogle Scholar
  123. 123.
    Lehrke M, et al. (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 1:e45.PubMedCentralCrossRefPubMedGoogle Scholar
  124. 124.
    Yang Q, et al. (2005) Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436:356–62.CrossRefGoogle Scholar
  125. 125.
    Graham TE, et al. (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N. Engl. J. Med. 354:2552–63.CrossRefGoogle Scholar
  126. 126.
    Haider DG, et al. (2007) Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J. Clin. Endocrinol. Metab. 92:1168–71.CrossRefGoogle Scholar
  127. 127.
    Jia W, et al. (2007) Association of serum retinol-binding protein 4 and visceral adiposity in Chinese subjects with and without type 2 diabetes. J. Clin. Endocrinol. Metab. 92:3224–9.CrossRefGoogle Scholar
  128. 128.
    Klöting N, et al. (2007) Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 6:79–87.CrossRefGoogle Scholar
  129. 129.
    Aeberli I, et al. (2007) Serum retinol-binding protein 4 concentration and its ratio to serum retinol are associated with obesity and metabolic syndrome components in children. J. Clin. Endocrinol. Metab. 92:4359–65.CrossRefGoogle Scholar
  130. 130.
    Möhlig M, et al. (2008) Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. Eur. J. Endocrinol. 158:517–23.CrossRefGoogle Scholar
  131. 131.
    Gavi S, et al. (2007) Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J. Clin. Endocrinol. Metab. 92:1886–90.CrossRefGoogle Scholar
  132. 132.
    Perseghin G, et al. (2007) Serum retinol-binding protein-4, leptin, and adiponectin concentrations are related to ectopic fat accumulation. J. Clin. Endocrinol. Metab. 92:4883–8.CrossRefGoogle Scholar
  133. 133.
    Stefan N, et al. (2007) High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care 30:1173–8.CrossRefGoogle Scholar
  134. 134.
    Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. (2007) Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J. Clin. Endocrinol. Metab. 92:2712–9.CrossRefGoogle Scholar
  135. 135.
    Cho YM, et al. (2006) Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 29:2457–61.CrossRefGoogle Scholar
  136. 136.
    Qi Q, et al. (2007) Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J. Clin. Endocrinol. Metab. 92:4827–34.CrossRefGoogle Scholar
  137. 137.
    Lim S, et al. (2008) Insulin-sensitizing effects of exercise on adiponectin and retinol binding protein-4 concentrations in young and middle-aged women. J. Clin. Endocrinol. Metab. 93:2263–8.CrossRefGoogle Scholar
  138. 138.
    Balagopal P, et al. (2007) Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J. Clin. Endocrinol. Metab. 92:1971–4.CrossRefGoogle Scholar
  139. 139.
    Munkhtulga L, et al. (2007) Identification of a regulatory SNP in the retinol binding protein 4 gene associated with type 2 diabetes in Mongolia. Hum. Genet. 120:879–88.CrossRefGoogle Scholar
  140. 140.
    Craig RL, Chu WS, Elbein SC. (2007) Retinol binding protein 4 as a candidate gene for type 2 diabetes and prediabetic intermediate traits. Mol. Genet. Metab. 90:338–44.CrossRefGoogle Scholar
  141. 141.
    Janke J, et al. (2006) Retinol-binding protein 4 in human obesity. Diabetes 55:2805–10.CrossRefGoogle Scholar
  142. 142.
    Yao-Borengasser A, et al. (2007) Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J. Clin. Endocrinol. Metab. 92:2590–7.PubMedCentralCrossRefPubMedGoogle Scholar
  143. 143.
    Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. (2007) Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 30:1802–6.CrossRefGoogle Scholar
  144. 144.
    von Eynatten M, et al. (2007) Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia 50:1930–7.CrossRefGoogle Scholar
  145. 145.
    Silha JV, Nyomba BL, Leslie WD, Murphy LJ. (2007) Ethnicity, insulin resistance, and inflammatory adipokines in women at high and low risk for vascular disease. Diabetes Care 30:286–91.CrossRefGoogle Scholar
  146. 146.
    Graham TE, Wason CJ, Blüher M, Kahn BB. (2007) Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulin-resistant human subjects. Diabetologia 50:814–23.CrossRefGoogle Scholar
  147. 147.
    von Eynatten M, Humpert PM. (2008) Retinol-binding protein-4 in experimental and clinical metabolic disease. Expert Rev. Mol. Diagn. 8:289–99CrossRefGoogle Scholar
  148. 148.
    Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. (1997) Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389:610–4.CrossRefGoogle Scholar
  149. 149.
    Jellema A, Plat J, Mensink RP. (2004) Weight reduction, but not a moderate intake of fish oil, lowers concentrations of inflammatory markers and PAI-1 antigen in obese men during the fasting and postprandial state. Eur. J. Clin. Invest. 34:766–73.CrossRefGoogle Scholar
  150. 150.
    Hotamisligil GS, Shargill NS, Spiegelman BM. (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1:87–91.CrossRefGoogle Scholar
  151. 151.
    Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK. (2006) Effects of etanercept in patients with the metabolic syndrome. Arch. Intern. Med. 166:902–8.PubMedCentralCrossRefPubMedGoogle Scholar
  152. 152.
    Dominguez H, et al. (2005) Metabolic and vascular effects of tumor necrosis factor-alpha blockade with etanercept in obese patients with type 2 diabetes. J. Vasc. Res. 42:517–25.CrossRefGoogle Scholar
  153. 153.
    Mooney RA. (2007) Counterpoint: interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102:816–8.CrossRefGoogle Scholar
  154. 154.
    Pedersen BK, Febbraio MA. (2007) Point: interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J. Appl. Physiol. 102:814–6.CrossRefGoogle Scholar
  155. 155.
    Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–9.CrossRefGoogle Scholar
  156. 156.
    Senn JJ, Klover PJ, Nowak IA, Mooney RA. (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–9.CrossRefGoogle Scholar
  157. 157.
    Rotter V, Nagaev I, Smith U. (2003) Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol. Chem. 278:45777–84.CrossRefGoogle Scholar
  158. 158.
    Carey AL, et al. (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–97.CrossRefGoogle Scholar
  159. 159.
    Al Khalili L, et al. (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol. Endocrinol. 20:3364–75.CrossRefGoogle Scholar
  160. 160.
    Kim HJ, et al. (2004). Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–7.CrossRefGoogle Scholar
  161. 161.
    Inoue H, et al. (2006) Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab. 3:267–75.CrossRefGoogle Scholar
  162. 162.
    Pickup JC, Mattock MB, Chusney GD, Burt D. (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286–92.PubMedCentralCrossRefPubMedGoogle Scholar
  163. 163.
    Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. (2001) Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 280:E745–51.CrossRefGoogle Scholar
  164. 164.
    Tilg H, Hotamisligil, GS. (2006) Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 131:934–45.CrossRefGoogle Scholar
  165. 165.
    Hida K, et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. U. S. A. 102:10610–5.PubMedCentralCrossRefPubMedGoogle Scholar
  166. 166.
    Klöting N, et al. (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339:430–6.CrossRefPubMedPubMedCentralGoogle Scholar
  167. 167.
    Youn BS, et al. (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57:372–7.CrossRefPubMedPubMedCentralGoogle Scholar
  168. 168.
    Samal B, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 14:1431–7.PubMedCentralCrossRefPubMedGoogle Scholar
  169. 169.
    Rongvaux A, et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32:3225–34.CrossRefGoogle Scholar
  170. 170.
    Fukuhara A, et al. (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307:426–30.CrossRefPubMedPubMedCentralGoogle Scholar
  171. 171.
    Chen MP, et al. (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 91:295–9.CrossRefGoogle Scholar
  172. 172.
    Haider DG, et al. (2006) Increased plasma vis-fatin concentrations in morbidly obese subjects are reduced after gastric banding. J. Clin. Endocrinol. Metab. 91:1578–81.CrossRefGoogle Scholar
  173. 173.
    Filippatos TD, et al. (2008) Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur. J. Clin. Invest. 38:71–2.CrossRefGoogle Scholar
  174. 174.
    Bailey SD, et al. (2006) Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes 55:2896–902.CrossRefGoogle Scholar
  175. 175.
    Zhang YY, et al. (2006) A visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity (Silver Spring) 14:2119–26.CrossRefGoogle Scholar
  176. 176.
    Berndt J, et al. (2005) Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 54:2911–6.CrossRefGoogle Scholar
  177. 177.
    Klöting N, et al. (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 339:430–6.CrossRefPubMedPubMedCentralGoogle Scholar
  178. 178.
    Pagano C, et al. (2006) Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J. Clin. Endocrinol. Metab. 91:3165–70.CrossRefGoogle Scholar
  179. 179.
    Oki K, Yamane K, Kamei N, Nojima H, Kohno N. (2007) Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin. Endocrinol. (Oxf). 67:796–800.CrossRefGoogle Scholar
  180. 180.
    Revollo JR, et al. (2007) Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 6:363–75.PubMedCentralCrossRefPubMedGoogle Scholar
  181. 181.
    Sell H, Eckel J. (2007) Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-alpha. Diabetologia 50:2221–3.CrossRefGoogle Scholar
  182. 182.
    Faggioni R, Feingold KR, Grunfeld C. (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J. 15:2565–71.CrossRefGoogle Scholar
  183. 183.
    Simons PJ, van den Pangaart PS, van Roomen CP, Aerts JM, Boon L. (2005) Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor-alpha- and interleukin-1beta-treated human preadipocytes are potent leptin producers. Cytokine 32:94–103.CrossRefGoogle Scholar
  184. 184.
    Hector J, et al. (2007) TNF-alpha alters visfatin and adiponectin levels in human fat. Horm. Metab. Res. 39:250–5.CrossRefGoogle Scholar
  185. 185.
    Lago F, Dieguez C, Gómez-Reino J, Gualillo O. (2007) Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol. 3:716–24CrossRefGoogle Scholar
  186. 186.
    Moschen AR, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomod-ulating properties. J. Immunol. 178:1748–58.CrossRefPubMedPubMedCentralGoogle Scholar
  187. 187.
    Asensio C, Cettour-Rose P, Theander-Carrillo C, Rohner-Jeanrenaud F, Muzzin P. (2004) Changes of glycemia by leptin administration or high fat feeding in rodent models of obesity/type 2 diabetes suggest a link between resistin expression and control of glucose homeostasis. Endocrinology 145:2206–13CrossRefGoogle Scholar
  188. 188.
    Zhang W, Della-Fera MA, Hartzell DL, Hausman D, Baile CA. (2008) Adipose tissue gene expression profiles in ob/ob mice treated with leptin. Life Sci. 83:35–42.CrossRefGoogle Scholar
  189. 189.
    Delporte ML, El Mkadem SA, Quisquater M, Brichard SM. (2004) Leptin treatment markedly increased plasma adiponectin but barely decreased plasma resistin of ob/ob mice. Am. J. Physiol. Endocrinol Metab. 287:E446–53.CrossRefGoogle Scholar
  190. 190.
    Obesity and overweight. c2008. Geneva: World Health Organization; [cited 2008 Oct 15]. Available from:

Copyright information

© Feinstein Institute for Medical Research 2008

Authors and Affiliations

  • Katja Rabe
    • 1
  • Michael Lehrke
    • 1
  • Klaus G. Parhofer
    • 1
  • Uli C. Broedl
    • 1
  1. 1.Department of Internal Medicine IIUniversity of MunichMunichGermany

Personalised recommendations